{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:20Z","timestamp":1783405220579,"version":"3.54.6"},"reference-count":137,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Friedreich's ataxia (FA) is a rare neurodegenerative disease with multisystemic symptoms that requires multidisciplinary care. This systematic review summarizes available pharmacological and nonpharmacological interventions, their outcomes, and alignment with patient\u2010centered care domains, as well as their impact on these domains. The publication search was conducted in three databases (PubMed, Embase, Cochrane Library) from 2010 to 2025 for human studies. Studies were included if they met predefined eligibility criteria (FA population\/pharmacological or nonpharmacological interventions\/use of comparator\/any outcomes, especially patient reported). All study designs were included. Risk of bias assessment was performed by two reviewers using Cochrane RoB\u20102 for randomized controlled trials and JBI Critical Appraisal Tools for case reports, case series, and quasi\u2010experimental studies. Results were synthesized narratively. Ninety studies (69 FA only, 21 mixed ataxia) were included. FA\u2010only studies included randomized controlled trials (32%), quasi\u2010experimental studies (35%), and case reports (33%), mostly with small samples (&lt;100) and low\u2010to\u2010moderate bias. Pharmacological interventions (66.7%), mainly disease modifying (93.5%), were more common than nonpharmacological interventions, with the most effective interventions being omaveloxolone (pharmacological), as well as rehabilitation and heart interventions (nonpharmacological). Pharmacological studies often showed biological improvements without clear clinical benefit, whereas nonpharmacological therapies yielded more consistent patient\u2010relevant gains, although evidence was limited. Physical health was the most frequently addressed domain (42.3%), whereas mental health and caregiver aspects were rarely studied (1.8% and 1.4%). No study investigated caregiver burden or economic outcomes. More holistic studies are needed, integrating patient\u2010 and caregiver\u2010reported outcomes and combining multiple treatment approaches in larger cohorts. \u00a9 2026 The Author(s).\n                    <jats:italic>Movement Disorders<\/jats:italic>\n                    published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                  <\/jats:p>","DOI":"10.1002\/mds.70423","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:43:26Z","timestamp":1783403006000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Key Interventions in Friedreich's Ataxia and Their Impact on Patient Outcomes: A Systematic Review"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-0544","authenticated-orcid":false,"given":"Dorota","family":"Sarwinska","sequence":"first","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Rostock\/Greifswald  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4486-8632","authenticated-orcid":false,"given":"Maresa","family":"Buchholz","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Rostock\/Greifswald  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Iskandar","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Rostock\/Greifswald  Greifswald Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-2134","authenticated-orcid":false,"given":"Marcus","family":"Grobe\u2010Einsler","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Bonn  Bonn Germany"},{"name":"Center for Neurology, Department of Parkinson's Disease, Sleep and Movement Disorders University Hospital Bonn  Bonn Germany"},{"name":"Department of Neurology Center for Movement Disorders and Neuromodulation, Medical Faculty, Heinrich\u2010Heine University  D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-5442","authenticated-orcid":false,"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Faber","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Bonn  Bonn Germany"},{"name":"Center for Neurology, Department of Parkinson's Disease, Sleep and Movement Disorders University Hospital Bonn  Bonn Germany"},{"name":"Department of Neuroradiology University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Michalowsky","sequence":"additional","affiliation":[{"name":"German Center for Neurodegenerative Diseases e.V., Site Rostock\/Greifswald  Greifswald Germany"},{"name":"McMaster University, Health Research Methods, Evidence and Impact  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jnc.12215","article-title":"Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co\u2010localize, suggesting a common Palaeolithic origin in the Franco\u2010Cantabrian ice age refuge","volume":"126","author":"Vankan P","year":"2013","journal-title":"J Neurochem"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/104.3.589","article-title":"FRIEDREICH'S ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features","volume":"104","author":"Harding AE","year":"1981","journal-title":"Brain"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archneur.59.5.743","article-title":"Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy","volume":"59","author":"Lynch DR","year":"2002","journal-title":"Arch Neurol"},{"issue":"1","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-020-01475-9","article-title":"Onset features and time to diagnosis in Friedreich's ataxia","volume":"15","author":"Indelicato E","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich ataxia: quantitative characterization over 5\u2009years","volume":"3","author":"Patel M","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jval.2023.09.177","article-title":"CO105 A retrospective study characterizing age at loss of ambulation among patients with Friedreich ataxia using health administrative claims data in the United States","volume":"26","author":"Salvucci A","year":"2023","journal-title":"Value Health"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive Disase caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano V","year":"1996","journal-title":"Science"},{"issue":"1","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/bmb\/ldx034","article-title":"Friedreich's ataxia: clinical features, pathogenesis and management","volume":"124","author":"Cook A","year":"2017","journal-title":"Br Med Bull"},{"issue":"1","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12883-022-02615-3","article-title":"The cognitive profile of Friedreich ataxia: a systematic review and meta\u2010analysis","volume":"22","author":"Naeije G","year":"2022","journal-title":"BMC Neurol"},{"issue":"5","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","article-title":"Progression characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS): a 4\u2010year cohort study","volume":"20","author":"Reetz K","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"12","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1007\/s10072-022-06360-w","article-title":"Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages","volume":"43","author":"Fichera M","year":"2022","journal-title":"Neurol Sci"},{"issue":"1","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijchp.2017.11.004","article-title":"Depressive symptoms in Friedreich ataxia","volume":"18","author":"Nieto A","year":"2018","journal-title":"Int J Clin Health Psychol"},{"issue":"4","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S1355617720000958","article-title":"Longitudinal study of cognitive functioning in Friedreich's ataxia","volume":"27","author":"Hernandez\u2010Torres A","year":"2021","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"29076","DOI":"10.1038\/s41598-024-80258-9","article-title":"Exploring neuropsychiatric symptoms in Friedreich ataxia","volume":"14","author":"Karamazovova S","year":"2024","journal-title":"Sci Rep"},{"key":"e_1_2_10_16_1","first-page":"28","article-title":"Symptom burden of people with progressive ataxia, and its wider impact on their friends and relatives: a cross\u2010sectional study","volume":"3","author":"Lowit A","year":"2021","journal-title":"AMRC Open Res"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116642","article-title":"Health related quality of life in Friedreich ataxia in a large heterogeneous cohort","volume":"410","author":"Xiong E","year":"2020","journal-title":"J Neurol Sci"},{"key":"e_1_2_10_18_1","volume-title":"Consensus guideline f\u00fcr klinisches management der Friedreich's Ataxie","author":"European Reference Network","year":"2019"},{"key":"e_1_2_10_19_1","unstructured":"Administration U.S.F.D.FDA approves first treatment for Friedreich's ataxia;2023. Accessed May 12 2025.https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-friedreichs-ataxia."},{"key":"e_1_2_10_20_1","unstructured":"Biogen.Biogen received european commission approval for SKYCLARYS\u00ae (omaveloxolone) the first therapy to treat Friedreich's Ataxia;2024. Accessed May 12 2025.https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-received-european-commission-approval-skyclarysr."},{"key":"e_1_2_10_21_1","unstructured":"Biogen Netherlands B.V.Summary of product characteristics Skyclarys."},{"issue":"1","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13023-024-03474-6","article-title":"Safety and efficacy of omaveloxolone v\/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16\u2009years: a systematic review","volume":"19","author":"Umrao A","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_10_23_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024)","author":"Higgins JPT","year":"2024"},{"issue":"7","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta\u2010analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","journal-title":"PLoS Med"},{"key":"e_1_2_10_25_1","unstructured":"PROSPERO home page; Accessed June 19 2025.https:\/\/www.crd.york.ac.uk\/PROSPERO\/."},{"issue":"1","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2010a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","journal-title":"Syst Rev"},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi\u2010experimental studies","volume":"22","author":"Barker TH","year":"2024","journal-title":"JBI Evid Synth"},{"issue":"10","key":"e_1_2_10_29_1","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"1","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041379","article-title":"Developing an evidence assessment framework and appraising the academic literature on migrant health in Malaysia: a scoping review","volume":"11","author":"Smalen AW","year":"2021","journal-title":"BMJ Open"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch S","year":"2014","journal-title":"Mov Disord"},{"issue":"7","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.apmr.2010.04.007","article-title":"Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia","volume":"91","author":"Drinkard BE","year":"2010","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy\u2010results from a 6\u2010month phase III study (IONIA)","volume":"161","author":"Lagedrost SJ","year":"2011","journal-title":"Am Heart J"},{"issue":"8","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double\u2010blind, placebo\u2010controlled trial of Idebenone in Friedreich ataxia","volume":"67","author":"Lynch DR","year":"2010","journal-title":"Arch Neurol"},{"issue":"3","key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acn3.731","article-title":"Randomized, double\u2010blind, placebo\u2010controlled study of interferon\u2010gamma 1b in Friedreich ataxia","volume":"6","author":"Lynch DR","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/mds.24066","article-title":"Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial","volume":"27","author":"Mariotti C","year":"2012","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and safety of Leriglitazone in patients with Friedreich ataxia: A phase 2 double\u2010blind, randomized controlled trial (FRAMES)","volume":"8","author":"Pandolfo M","year":"2022","journal-title":"Neurol Genet"},{"issue":"6","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acn3.51373","article-title":"Results of a randomized double\u2010blind study evaluating luvadaxistat in adults with Friedreich ataxia","volume":"8","author":"Wang H","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12311-013-0482-y","article-title":"Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open\u2010label trial","volume":"12","author":"Arpa J","year":"2013","journal-title":"Cerebellum"},{"issue":"3","key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1535370219890873","article-title":"Effects of tocotrienol supplementation in Friedreich's ataxia: A model of oxidative stress pathology","volume":"245","author":"Bolotta A","year":"2020","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10072-015-2427-3","article-title":"GIFT\u20101, a phase IIa clinical trial to test the safety and efficacy of IFNgamma administration in FRDA patients","volume":"37","author":"Marcotulli C","year":"2016","journal-title":"Neurol Sci"},{"issue":"2","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-011-6174-y","article-title":"Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6\u2010month controlled study followed by a 12\u2010month open\u2010label extension study","volume":"259","author":"Meier T","year":"2012","journal-title":"J Neurol"},{"issue":"4","key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6\u2010month randomized controlled trial","volume":"76","author":"Pandolfo M","year":"2014","journal-title":"Ann Neurol"},{"issue":"7","key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/mds.29808","article-title":"Calcitriol treatment is safe and increases frataxin levels in Friedreich ataxia patients","volume":"39","author":"Alemany\u2010Perna B","year":"2024","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mus.26610","article-title":"Open\u2010label pilot study of oral methylprednisolone for the treatment of patients with friedreich ataxia","volume":"60","author":"Patel M","year":"2019","journal-title":"Muscle Nerve"},{"issue":"6","key":"e_1_2_10_47_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/ane.13088","article-title":"Patient\u2010reported outcomes in Friedreich's ataxia after withdrawal from idebenone","volume":"139","author":"Cook A","year":"2019","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch DR","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of Omaveloxolone in Friedreich ataxia (MOXIe study)","volume":"89","author":"Lynch DR","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of Omaveloxolone in Friedreich ataxia (MOXIe study)\u2010correction","volume":"89","author":"Lynch DR","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"e_1_2_10_51_1","article-title":"A pilot phase 2 randomized trial to evaluate the safety and potential efficacy of etravirine in Friedreich ataxia patients","volume":"11","author":"Paparella G","year":"2024","journal-title":"Children (Basel)"},{"issue":"9","key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/0883073812448229","article-title":"Cardiac transplantation in Friedreich ataxia","volume":"27","author":"Yoon G","year":"2012","journal-title":"J Child Neurol"},{"issue":"9","key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.healun.2016.06.021","article-title":"Friedreich's ataxia and advanced heart failure: an ethical conundrum in decision\u2010making","volume":"35","author":"Ivak P","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jns.2017.01.027","article-title":"Cardiac transplantation in Friedreich ataxia: extended follow\u2010up","volume":"375","author":"McCormick A","year":"2017","journal-title":"J Neurol Sci"},{"issue":"2","key":"e_1_2_10_55_1","first-page":"201","article-title":"Disabilit\u00e0 e terapia occupazionale nei pazienti con atassia di Friedreich","volume":"33","author":"Ciancarelli I","year":"2011","journal-title":"G Ital Med Lav Ergon"},{"issue":"1","key":"e_1_2_10_56_1","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.CC.L.00056","article-title":"Posterior spinal fusion for Friedreich ataxia\u2010related scoliosis in twin girls, A case report","volume":"3","author":"Leighton J","year":"2013","journal-title":"J Bone Joint Surg Case Connector"},{"key":"e_1_2_10_57_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1270296","article-title":"Effectiveness of rehabilitation intervention in persons with Friedreich ataxia","volume":"14","author":"Paparella G","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ane.12337","article-title":"Open\u2010label pilot study of interferon gamma\u20101b in Friedreich ataxia","volume":"132","author":"Seyer L","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"9942","key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high\u2010dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open\u2010label, dose\u2010escalation study","volume":"384","author":"Libri V","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"e_1_2_10_60_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long\u2010term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia","volume":"31","author":"Sacca F","year":"2016","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","article-title":"An open\u2010label trial in Friedreich ataxia suggests clinical benefit with high\u2010dose resveratrol, without effect on frataxin levels","volume":"262","author":"Yiu EM","year":"2015","journal-title":"J Neurol"},{"issue":"2","key":"e_1_2_10_62_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mds.27979","article-title":"Safety and efficacy of interferon gamma in friedreich's ataxia","volume":"35","author":"Vavla M","year":"2020","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_2_10_63_1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mds.27353","article-title":"Randomized, clinical trial of RT001: early signals of efficacy in Friedreich's ataxia","volume":"33","author":"Zesiewicz T","year":"2018","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_2_10_64_1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.neuroscience.2010.09.013","article-title":"Successful treatment of auditory perceptual disorder in individuals with Friedreich ataxia","volume":"171","author":"Rance G","year":"2010","journal-title":"Neuroscience"},{"issue":"2","key":"e_1_2_10_65_1","first-page":"139","article-title":"Whole\u2010body vibration alters blood flow velocity and neuromuscular activity in Friedreich's ataxia","volume":"31","author":"Herrero AJ","year":"2011","journal-title":"Clin Physiol Funct Imaging"},{"issue":"5","key":"e_1_2_10_66_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1179\/1754762813Y.0000000029","article-title":"Bilateral cochlear implantation in Friedreich's ataxia: A case study","volume":"14","author":"Frewin B","year":"2013","journal-title":"Cochlear Implants Int"},{"issue":"5","key":"e_1_2_10_67_1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0269215517736903","article-title":"Can rehabilitation improve the health and well\u2010being in Friedreich's ataxia: a randomized controlled trial?","volume":"32","author":"Milne SC","year":"2018","journal-title":"Clin Rehabil"},{"issue":"2","key":"e_1_2_10_68_1","first-page":"81","article-title":"Evaluation of neuropsychological functions in patients with Friedreich ataxia before and after cognitive therapy","volume":"25","author":"Ciancarelli I","year":"2010","journal-title":"Funct Neurol"},{"issue":"2","key":"e_1_2_10_69_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nrleng.2017.11.004","article-title":"Compassionate use of human recombinant insulin\u2010like growth factor\u20101 therapy in Friedreich's ataxia","volume":"35","author":"Garcia Ron A","year":"2020","journal-title":"Neurolog\u00eda (English Edition)"},{"issue":"11","key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00415-016-8244-7","article-title":"Long\u2010term treatment with thiamine as possible medical therapy for Friedreich ataxia","volume":"263","author":"Costantini A","year":"2016","journal-title":"J Neurol"},{"issue":"8","key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/mds.29453","article-title":"Anodal cerebellar transcranial direct current stimulation reduces motor and cognitive symptoms in Friedreich's ataxia: A randomized, sham\u2010controlled trial","volume":"38","author":"Naeije G","year":"2023","journal-title":"Mov Disord"},{"issue":"8","key":"e_1_2_10_72_1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.25058","article-title":"A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial","volume":"27","author":"Lynch DR","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nmt-2018-0013","article-title":"Double\u2010blind, randomized and controlled trial of EPI\u2010743 in Friedreich's ataxia","volume":"8","author":"Zesiewicz T","year":"2018","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.29286","article-title":"Efficacy of Omaveloxolone in Friedreich's ataxia: delayed\u2010start analysis of the MOXIe extension","volume":"38","author":"Lynch DR","year":"2023","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_2_10_75_1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","article-title":"Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia","volume":"270","author":"Lynch DR","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"e_1_2_10_76_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","article-title":"Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia\u2013a dose\u2010response trial","volume":"10","author":"Nachbauer W","year":"2011","journal-title":"Cerebellum"},{"issue":"4","key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.23435","article-title":"Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit","volume":"26","author":"Sacca F","year":"2011","journal-title":"Mov Disord"},{"issue":"4","key":"e_1_2_10_78_1","article-title":"A longitudinal VBM study monitoring treatment with erythropoietin in patients with Friedreich ataxia","volume":"3","author":"Santner W","year":"2014","journal-title":"Acta Radiol Short Rep"},{"issue":"1","key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s13023-022-02568-3","article-title":"Clinical management guidelines for Friedreich ataxia: best practice in rare diseases","volume":"17","author":"Corben LA","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1212\/WNL.0000000000201598","article-title":"Patient\u2010reported impact of symptoms in Friedreich ataxia","volume":"100","author":"Seabury J","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"e_1_2_10_81_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40279-015-0303-1","article-title":"Quantifying the placebo effect in psychological outcomes of exercise training: a meta\u2010analysis of randomized trials","volume":"45","author":"Lindheimer JB","year":"2015","journal-title":"Sports Med"},{"issue":"8","key":"e_1_2_10_82_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/09638288.2016.1277400","article-title":"The meanings of physiotherapy and exercise for people living with progressive cerebellar ataxia: an interpretative phenomenological analysis","volume":"40","author":"Cassidy E","year":"2018","journal-title":"Disabil Rehabil"},{"issue":"1","key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00415-020-10306-7","article-title":"Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo\u2010controlled trials","volume":"269","author":"Choi JH","year":"2022","journal-title":"J Neurol"},{"issue":"7","key":"e_1_2_10_84_1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","article-title":"Friedreich's ataxia\u2010a rare multisystem disease","volume":"24","author":"Reetz K","year":"2025","journal-title":"Lancet Neurol"},{"issue":"10","key":"e_1_2_10_85_1","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s11606-015-3288-4","article-title":"Different measures, different outcomes? A systematic review of performance\u2010based versus self\u2010reported measures of health literacy and numeracy","volume":"30","author":"Kiechle ES","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"1","key":"e_1_2_10_86_1","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1038\/s41598-020-61834-1","article-title":"Relationship between self\u2010reported and objectively measured manual ability varies during the first year post\u2010stroke","volume":"10","author":"Hussain N","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_2_10_87_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/acn3.51897","article-title":"Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data","volume":"11","author":"Lynch DR","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"e_1_2_10_88_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s12311-023-01547-z","article-title":"Consensus recommendations for clinical outcome assessments and registry development in ataxias: ataxia global initiative (AGI) working group expert guidance","volume":"23","author":"Klockgether T","year":"2024","journal-title":"Cerebellum"},{"issue":"4","key":"e_1_2_10_89_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-025-01065-y","article-title":"A global perspective on research advances and future challenges in Friedreich ataxia","volume":"21","author":"Indelicato E","year":"2025","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"e_1_2_10_90_1","doi-asserted-by":"crossref","DOI":"10.1007\/s12311-026-02020-3","article-title":"A patient\u2010reported outcome measure of communication difficulties in Friedreich ataxia: COMATAX","volume":"25","author":"Buchholz M","year":"2026","journal-title":"Cerebellum"},{"issue":"4","key":"e_1_2_10_91_1","doi-asserted-by":"crossref","first-page":"82E","DOI":"10.1179\/jmt.2008.16.4.82E","article-title":"Clinimetrics corner: the minimal clinically important change score (MCID): A necessary pretense","volume":"16","author":"Cook CE","year":"2008","journal-title":"J Man Manip Ther"},{"key":"e_1_2_10_92_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-015-0328-4","article-title":"Friedreich ataxia in Norway\u2010an epidemiological, molecular and clinical study","volume":"10","author":"Wedding IM","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"e_1_2_10_93_1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12311-012-0424-0","article-title":"Neuroanatomical correlates of depression in Friedreich's ataxia: a voxel\u2010based morphometry study","volume":"12","author":"Silva CB","year":"2013","journal-title":"Cerebellum"},{"issue":"6","key":"e_1_2_10_94_1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00415-023-11623-3","article-title":"Determinant of the cerebellar cognitive affective syndrome in Friedreich's ataxia","volume":"270","author":"Destrebecq V","year":"2023","journal-title":"J Neurol"},{"issue":"8","key":"e_1_2_10_95_1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/acn3.315","article-title":"Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study","volume":"3","author":"Dogan I","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"e_1_2_10_96_1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12311-017-0890-5","article-title":"Personality and neuropsychological profiles in Friedreich ataxia","volume":"17","author":"Sayah S","year":"2018","journal-title":"Cerebellum"},{"key":"e_1_2_10_97_1","article-title":"Exploration of transitional life events in individuals with Friedreich ataxia: implications for genetic counseling","author":"White VB","year":"2010","journal-title":"Behav Brain Funct"},{"issue":"6","key":"e_1_2_10_98_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0883073818764941","article-title":"Impact of mobility device use on quality of life in children with Friedreich ataxia","volume":"33","author":"Ejaz R","year":"2018","journal-title":"J Child Neurol"},{"issue":"2","key":"e_1_2_10_99_1","first-page":"822","article-title":"The emotional and physical problems of people with Friedreich's ataxia and their perception about discrimination","volume":"21","author":"Karatas D","year":"2024","journal-title":"Kahramanmaras Sutcu Imam Univ Soc Sci J"},{"issue":"8","key":"e_1_2_10_100_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-1172-8-38","article-title":"Impact of Friedreich's ataxia on health\u2010care resource utilization in the United Kingdom and Germany","volume":"28","author":"Giunti P","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_10_101_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00066","article-title":"Burden of Friedreich's ataxia to the patients and healthcare Systems in the United States and Canada","volume":"4","author":"Polek B","year":"2013","journal-title":"Front Pharmacol"},{"key":"e_1_2_10_102_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1267099","article-title":"Effectiveness and cost of integrated cognitive and balance training for balance and falls in cerebellar ataxia: a blinded two\u2010arm parallel group RCT","volume":"14","author":"Winser SJ","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"e_1_2_10_103_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12311-021-01271-6","article-title":"The cost of living with inherited ataxia in Ireland","volume":"21","author":"Kelly MJ","year":"2022","journal-title":"Cerebellum"},{"issue":"8","key":"e_1_2_10_104_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075736","article-title":"Patient\u2010reported, health economic and psychosocial outcomes in patients with Friedreich ataxia (PROFA): protocol of an observational study using momentary data assessments via mobile health app","volume":"13","author":"Buchholz M","year":"2023","journal-title":"BMJ Open"},{"key":"e_1_2_10_105_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101552","article-title":"Patient\u2010reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA study","volume":"61","author":"Grobe\u2010Einsler M","year":"2026","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"e_1_2_10_106_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-021-02091-x","article-title":"The attitude of patients with progressive ataxias towards clinical trials","volume":"17","author":"Thomas\u2010Black G","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_10_107_1","unstructured":"University of Florida.Respiratory Training in Friedreich's Ataxia\u2010Clinical Study Protocol;2025.https:\/\/clinicaltrials.gov\/study\/NCT06539598."},{"key":"e_1_2_10_108_1","unstructured":"IRCCS Eugenio Medea.Efficacy of Stabilometric Platform to Improve Standing Balance in Patients With Friedreich's Ataxia\u2010Clinical Study Protocol;2025.https:\/\/clinicaltrials.gov\/study\/NCT06692296."},{"key":"e_1_2_10_109_1","unstructured":"The University of Melbourne.Speech rehabilitation for dysarthria resulting from spinocerebellar ataxia or Friedreich ataxia;2025.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12616001582448."},{"key":"e_1_2_10_110_1","unstructured":"The University of Melbourne.SpeechATAX: A 2\u2010arm examiner\u2010blinded wait\u2010list control group randomized controlled trial of intensive home based biofeedback driven speech rehabilitation in hereditary ataxia;2025.https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12618000519257."},{"key":"e_1_2_10_111_1","unstructured":"Children's Hospital of Philadelphia.NAD+ and Exercise in FA (ExRx in FA);2025.https:\/\/clinicaltrials.gov\/study\/NCT04192136."},{"key":"e_1_2_10_112_1","unstructured":"Friedreich's Ataxia Research Alliance.Friedreich's Ataxia drug development pipeline.Downingtown PA:Friedreich's Ataxia Research Alliance;2025."},{"key":"e_1_2_10_113_1","unstructured":"Freidreich's Ataxia Research Aliance.Improve Mitochondrial Function & Reduce Oxidative Stress Vatiquinone (PTC\u2010743);2025. Accessed August28 2025.https:\/\/www.curefa.org\/drug-development\/vatiquinone-ptc-743\/."},{"key":"e_1_2_10_114_1","unstructured":"The National Institute of Neurological Disorders and Stroke.Start\u2010up resource\u2013NINDS Friedreich's ataxia CDE recommendations;2023."},{"issue":"2","key":"e_1_2_10_115_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.25201","article-title":"Common data elements for clinical research in Friedreich's ataxia","volume":"28","author":"Lynch DR","year":"2013","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_116_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pediatrneurol.2010.01.004","article-title":"Intermediate\u2010dose idebenone and quality of life in Friedreich ataxia","volume":"42","author":"Brandsema JF","year":"2010","journal-title":"Pediatr Neurol"},{"issue":"5","key":"e_1_2_10_117_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.29271\/jcpsp.2022.05.671","article-title":"Neurological recovery with interferon\u2010gamma treatment in Friedreich's ataxia","volume":"32","author":"Tekin HG","year":"2022","journal-title":"J Coll Physicians Surg Pak"},{"issue":"5","key":"e_1_2_10_118_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jon.12050","article-title":"White matter changes in patients with friedreich ataxia after treatment with erythropoietin","volume":"24","author":"Egger K","year":"2014","journal-title":"J Neuroimaging"},{"key":"e_1_2_10_119_1","doi-asserted-by":"crossref","first-page":"bcr2013009424","DOI":"10.1136\/bcr-2013-009424","article-title":"High\u2010dose thiamine improves the symptoms of Friedreich's ataxia","volume":"2013","author":"Costantini A","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"1","key":"e_1_2_10_120_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2053-8871-1-10","article-title":"IGF\u20101 in Friedreich's ataxia \u2013 proof\u2010of\u2010concept trial","volume":"1","author":"Sanz\u2010Gallego I","year":"2014","journal-title":"Cerebellum Ataxias"},{"issue":"8","key":"e_1_2_10_121_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/0883073816636087","article-title":"Clinical experience with deferiprone treatment for Friedreich ataxia","volume":"31","author":"Elincx\u2010Benizri S","year":"2016","journal-title":"J Child Neurol"},{"issue":"2","key":"e_1_2_10_122_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jimd.12285","article-title":"Safety and efficacy of (+)\u2010epicatechin in subjects with Friedreich's ataxia: A phase II, open\u2010label, prospective study","volume":"44","author":"Qureshi MY","year":"2021","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"e_1_2_10_123_1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134221","article-title":"Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia","volume":"5","author":"Igoillo\u2010Esteve M","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"e_1_2_10_124_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000356823","article-title":"Does intrathecal baclofen have a place in the treatment of painful spasms in friedreich ataxia? Case rep neurol","volume":"5","author":"Berntsson SG","year":"2013","journal-title":"Case Rep Neurol"},{"issue":"2","key":"e_1_2_10_125_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000489220","article-title":"Intrathecal baclofen therapy for painful muscle spasms in a patient with Friedreich's ataxia","volume":"96","author":"Kalyvas AV","year":"2018","journal-title":"Stereotact Funct Neurosurg"},{"issue":"8","key":"e_1_2_10_126_1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00347-015-0191-7","article-title":"Memantine for optic nerve atrophy in Friedreich's ataxia","volume":"113","author":"Peter S","year":"2016","journal-title":"Ophthalmologe"},{"key":"e_1_2_10_127_1","first-page":"3","article-title":"Improvements in quality of life in individuals with Friedreich's ataxia after participation in a 5\u2010year program of physical activity: an observational study pre\u2010post test design, and two years follow\u2010up","volume":"01","author":"Seco J.","year":"2014","journal-title":"Int J Neurorehabil"},{"issue":"3","key":"e_1_2_10_128_1","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.16965\/ijpr.2023.110","article-title":"Intensive multimodal treatment for A young adult with Friedreich ataxia: A case report","volume":"11","author":"Battal G","year":"2023","journal-title":"Int J Physiother Res"},{"issue":"2","key":"e_1_2_10_129_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2298\/VSP220209027S","article-title":"Efficiency of a 3\u2010week multicomponent rehabilitation on improving the function in a patient with Friedreich's ataxia: A case report","volume":"80","author":"Samardzic V","year":"2023","journal-title":"Vojnosanit Pregl"},{"issue":"3","key":"e_1_2_10_130_1","article-title":"Friedreich's ataxia: dance and somatic education a case report","volume":"24","author":"Teixeira FAC","year":"2018","journal-title":"Motriz Rev Educ Fis"},{"issue":"3","key":"e_1_2_10_131_1","article-title":"Should advanced Friedreich's ataxia Be a contraindication for heart transplantation? A case report of a successful procedure in a 58\u2010year\u2010old patient","volume":"9","author":"Valero MJ","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"e_1_2_10_132_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S104795111500013X","article-title":"Septal myectomy for hypertrophic obstructive cardiomyopathy in Friedreich's ataxia","volume":"26","author":"Anderson HN","year":"2016","journal-title":"Cardiol Young"},{"issue":"2","key":"e_1_2_10_133_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/pace.15125","article-title":"Tachycardiomyopathy treated with ablation by using 3D mapping system in a patient with Friedreich ataxia","volume":"48","author":"Hayiroglu MI","year":"2025","journal-title":"Pacing Clin Electrophysiol"},{"issue":"8","key":"e_1_2_10_134_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014447","article-title":"The role of robotic gait training and tDCS in Friedrich ataxia rehabilitation: A case report","volume":"98","author":"Portaro S","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"e_1_2_10_135_1","first-page":"18","article-title":"Interven\u00e7\u00e3o Terap\u00eautica Ocupacional junto \u00e0 duas jovens com Ataxia de Friedreich:um relato de caso","volume":"15","author":"Freitas Zanona A","year":"2015","journal-title":"Rev Ocup Hum"},{"issue":"1","key":"e_1_2_10_136_1","doi-asserted-by":"crossref","DOI":"10.3390\/muscles4010001","article-title":"Muscle endurance training in a person with Friedreich's ataxia","volume":"4","author":"McGarrell NT","year":"2025","journal-title":"Muscles"},{"issue":"3","key":"e_1_2_10_137_1","article-title":"Improving oral communication in a jornalism student with Friedreich ataxia: A case report","volume":"27","author":"Batista DDJ","year":"2025","journal-title":"Rev CEFAC"},{"issue":"4","key":"e_1_2_10_138_1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12311-022-01393-5","article-title":"Quality of Life Changes Following the Onset of Cerebellar Ataxia: Symptoms and Concerns Self\u2010reported by Ataxia Patients and Informants","volume":"21","author":"Joyce MR","year":"2022","journal-title":"Cerebellum"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.70423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:44:00Z","timestamp":1783403040000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.70423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":137,"alternative-id":["10.1002\/mds.70423"],"URL":"https:\/\/doi.org\/10.1002\/mds.70423","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"2025-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mds.70423"}}